Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
Read original at benzingaStocks · News reference
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 1:49 PM
- Checked
- Jul 23, 2026, 1:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
Read original at benzingaDyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Read original at benzinga8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-07-29 AccNo: 0001193125-26-323940 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar